Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

Benzinga · 06/24 12:38
Guggenheim analyst Michael Schmidt reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.